This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Aliases (7)
Overview
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). It is the first dual incretin agonist and produces greater weight loss than semaglutide in head-to-head trials.
Key Benefits
Produces 15-22% body weight loss in obesity (greater than GLP-1 monotherapy), excellent glycemic control in type 2 diabetes, suppresses appetite and slows gastric emptying, and may improve cardiovascular and renal outcomes (under investigation).
Mechanism of Action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 activation enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central pathways. Adding GIP agonism amplifies insulinotropic and lipolytic effects synergistically.
Molecular Information
Weight
4,813.55 Da
Length
39 amino acids
Type
Dual GLP-1/GIP agonist
Amino Acid Sequence:
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys
* C20 fatty diacid conjugation for once-weekly dosing
Pharmacokinetics
▸ Reconstitution Lyophilized peptide
Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.
- 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
- 2 Draw the planned diluent volume into a 1 mL syringe.
- 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
- 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
- 5 Label vial with date reconstituted; refrigerate 2-8 °C.
- 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
Research Indications
Severe Obesity Management
Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide
Metabolic Syndrome Reversal
Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers
Body Composition Optimization
Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein
Type 2 Diabetes Management
FDA-approved for T2DM with superior HbA1c reduction (1.5-2.4%) compared to existing GLP-1 agonists and insulin regimens
Insulin Resistance Improvement
Significantly improves insulin sensitivity indices and glucose tolerance in prediabetic, diabetic, and metabolically healthy obese populations
Beta Cell Preservation
Protects pancreatic beta cell function and may help restore glucose-responsive insulin secretion in early diabetes
Peptide Interactions
essential adjunct to preserve lean mass. Not optional for any user, especially athletes.
lean-mass preservation in caloric deficit
support metabolic flux, counter potential micronutrient gaps from reduced intake
supports bone density during rapid weight loss (GIP arm may be partly bone-protective but adjunct still wise)
GI symptom management + electrolyte balance during nausea/diarrhea phases
anti-inflammatory adjunct
typically additive on lipid panel improvements
complementary glycemic + cardiovascular + renal mechanisms; common dual-prescribing pattern in modern T2D management
(semaglutide, retatrutide, liraglutide, exenatide, dulaglutide): redundant target, multiplicative GI toxicity, no additional efficacy ceiling. Pick one.
hypoglycemia risk
(anticholinergics, opioids): compounds GI burden
the conceptual mismatch — using a catabolic-leaning agent simultaneously with anabolic agents — flags confused goals
Both are GLP-1 agonists - combining increases hypoglycemia and severe GI side effect risk
Another GLP-1 agonist - dual therapy contraindicated due to additive effects
Quality Indicators
White to off-white lyophilized powder
Properly freeze-dried tirzepatide appears as light, fluffy powder cake without clumping
Clear reconstituted solution
Should be completely clear and colorless after proper reconstitution - no particles or cloudiness
Intact vial seal and proper labeling
Rubber stopper should be intact, clear mg dosage labeling, batch numbers, and expiration dates visible
Proper storage maintenance
Stored at correct temperature (2-8°C), protected from light, never frozen or overheated
Clumping, discoloration, or moisture
Powder should not be clumped, yellow/brown colored, or show signs of moisture damage or melting
Persistent cloudiness after reconstitution
Cloudiness that doesn't clear after proper mixing indicates protein aggregation or contamination
Unusual crystallization patterns
Large crystals or unusual formations may indicate storage temperature fluctuations or degradation
What to Expect
- OnsetAppetite suppression typically begins within 24-72 hr of first injection; "food noise" silencing reported within first week. Weight loss begins gradually as…
- Peakeffect: Maximal suppression at maintenance dose (10, 12.5, or 15 mg weekly for obesity; 5-15 mg for T2D). Plateau after 12-18 months for most users; SURMOUNT…
Side Effects & Safety
- Common (>10%):
- Nausea (~25-30% across SURMOUNT and SURPASS trials)
- Diarrhea (~21%)
- Decreased appetite (intended effect, can become problematic)
- Vomiting (~10%)
- Constipation (~17%, often cycling with diarrhea)
- Abdominal pain (~10-15%)
- Fatigue (~7-10%, especially during titration)
- Resting heart rate ↑ ~3-5 bpm
- Injection-site reactions (mild)
- Less common (1-10%):
- Gallbladder events (cholelithiasis, cholecystitis from rapid weight loss): ~2-3%
- Lipase / amylase elevations (asymptomatic)
- Hair shedding (telogen effluvium, weight-loss-mediated)
- Hypoglycemia in combination with insulin / sulfonylureas
- Sulfur burps, GERD/reflux
- Mild blood pressure reduction
- Eructation (~5-10%, more reported on tirzepatide than semaglutide)
- Rare-serious (<1% but worth knowing):
- Acute pancreatitis — class-wide risk. Hospitalize if persistent severe abdominal pain radiating to back. Discontinue permanently if confirmed.
- Acute kidney injury in setting of severe vomiting/diarrhea-driven dehydration
- Medullary thyroid carcinoma / C-cell hyperplasia — boxed warning based on rodent data; no human cases confirmed in 4+ years of tirzepatide use across millions of patients. Contraindicated in personal/family history of MTC or MEN-2.
- Diabetic retinopathy worsening — observed in subset of T2D patients with rapid glycemic improvement; not relevant in non-diabetics
- Gastroparesis — extreme delayed gastric emptying, sometimes persistent after discontinuation. Class-wide concern raised in 2023 case reports; quantification ongoing.
- Severe hypoglycemia — rare without concurrent insulin / sulfonylurea
- Pregnancy: oral contraceptive failure — tirzepatide reduces oral contraceptive exposure (likely via delayed gastric emptying); switch to non-oral contraception or use barrier method during initiation and dose escalation. Specifically labeled for tirzepatide.
- Specific watch periods:
- First 4-8 weeks of each dose escalation — peak GI risk
- Months 0-9 — peak gallbladder event risk during rapid weight loss
- Pre-procedure (anesthesia): delayed gastric emptying creates aspiration risk; ASA 2023 guidance recommends holding GLP-1/GIP class ≥1 week before elective procedures requiring sedation
- Females of reproductive potential during titration — contraceptive failure window
- Athletic-specific risk (the the user reason):
- Lean-mass loss — ~25-40% of total weight lost can be lean tissue without aggressive protein + resistance training adjuncts. Even at "spared" rates, an athlete in a forced caloric deficit will lose muscle. Tirzepatide's superior weight-loss potency means more absolute lean-mass loss per cycle vs. semaglutide.
- Cardio capacity — caloric deficit + reduced food intake at training volumes >10 hr/wk creates systemic energy crisis; aerobic capacity drops as glycogen stores deplete
- Recovery — protein synthesis depends on adequate amino acid pools and caloric availability; tirzepatide actively works against both
- Reaction time / cognitive sport-relevant function — no dedicated study, but caloric deficit + GI burden during training would plausibly degrade reaction time and decision-making in training
- No legitimate athletic-cutting role — even in compliant weight-class cuts, the drug-induced anorectic state makes refeed/recovery unpredictable and the lean-mass arithmetic worse than dietary cutting
References
SURPASS-2 (Frías et al., NEJM 2021)
Phase 3 head-to-head vs. semaglutide 1 mg in T2D
View StudySURMOUNT-1 (Jastreboff et al., NEJM 2022)
Phase 3 obesity primary efficacy trial, 20.9% weight loss at 15 mg
View StudySURMOUNT-2 (Garvey et al., Lancet 2023)
01200-X/fulltext) — Phase 3 obesity + T2D, 14.7% weight loss
View StudySURMOUNT-3 (Wadden et al., Nature Medicine 2023)
Phase 3 obesity with intensive lifestyle lead-in
View StudySURMOUNT-4 (Aronne et al., JAMA 2024)
Phase 3 maintenance / withdrawal
View StudySURMOUNT-5 head-to-head (Aronne et al., NEJM 2024)
Phase 3 head-to-head vs. semaglutide in obesity, 20.2% vs. 13.7% weight loss
View StudySURMOUNT-OSA (Malhotra et al., NEJM 2024)
Phase 3 obstructive sleep apnea + obesity, established OSA indication
View StudySUMMIT HFpEF (Packer et al., NEJM 2024)
HFpEF + obesity, 38% HF event reduction
View StudyLancet Diabetes & Endo: GLP-1 PGx GWAS (2022)
00340-0/fulltext) — GLP1R rs6923761 effect on response
View StudyPMC: Tirzepatide pharmacogenomics (2025)
emerging dual-agonist PGx
View StudyPMC: GLP-1 rebound meta-analysis (2025)
Class-wide weight regain
View StudyPMC: Saving muscle on GLP-1s (2025)
Protein + resistance training adjuncts
View StudyTCTMD: Don't worry about muscle loss (2024)
Counter-viewpoint on lean-mass concerns
View StudyClinicalTrials.gov: SURPASS-CVOT (NCT04255433)
Cardiovascular outcomes trial
View StudyLatest research
- rctSURMOUNT-5 — Tirzepatide vs semaglutide head-to-head for obesity (NEJM)72 weeks; tirzepatide produced 20.2% weight loss vs 13.7% on semaglutide. First direct head-to-head; establishes superior potency at maximum tolerated dose.
- rctSUMMIT — Tirzepatide in HFpEF with obesity (NEJM)38% reduction in worsening-HF or CV death; significant KCCQ-CSS improvement. Establishes class effect in HFpEF + obesity beyond semaglutide.
- rctSURMOUNT-OSA — Tirzepatide for moderate-to-severe OSA in adults with obesity (NEJM)AHI reduction ~25-29 events/h vs ~5 placebo at 52 weeks across two trials; basis for first GLP-1-class FDA OSA approval (Zepbound, Dec 2024).
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.